Home

Claudio Nessi

CIK 1722050 · last filed 2021-10-14

Claudio Nessi is a corporate insider who has filed 6 SEC Form 4 insider transactions across 3 companies since 2017. The most recent filing, for THRX, was dated Oct 14, 2021. Across all open-market trades the lifetime net is +$69.3M, making them a net buyer over the disclosed history. 13 SEC filings were submitted jointly with Anne-Mari Paster.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

6

Lifetime Open-Market Net

$69.30M

Filer Profile

Reported Address
C/O NEOMED
7 PLACE DU MOLARD
1204 GENEVA, V8 1204
Related Filers
Anne-Mari Paster — 13 joint filings, latest 2023-11-09
Otello Stampacchia — 13 joint filings, latest 2023-11-09
Omega Fund V GP Manager, Ltd. — 9 joint filings, latest 2021-02-12
Omega Fund V GP, L.P. — 9 joint filings, latest 2021-02-12
Omega Fund V, L.P. — 9 joint filings, latest 2021-02-12
Richard J. Lim — 5 joint filings, latest 2019-07-01
Omega Fund VI GP Manager, Ltd. — 4 joint filings, latest 2023-11-09
Omega Fund VI, L.P. — 4 joint filings, latest 2023-11-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Theseus Pharmaceuticals, Inc. (THRX) Delisted 711,479 $4.06 $2.89M $15.00M 1 2021-10-14
Kronos Bio, Inc. (KRON) Delisted 10%+ Owner 1,625,671 $0.88 $1.43M $51.30M 1 2020-10-16
X4 Pharmaceuticals, Inc (ASNS) Delisted Director 481 $0.08 $37 $3.00M 4 2018-06-07

Recent Filings

6 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-10-14 Theseus Pharmaceuticals, Inc. (THRX) Delisted Mixed +3,557,395 $15.00M EDGAR
2020-10-16 Kronos Bio, Inc. (KRON) Delisted Mixed +22,792,992 $86.79M EDGAR
2018-06-07 X4 Pharmaceuticals, Inc (ASNS) Delisted Grant (A) — $0 EDGAR
2018-03-05 X4 Pharmaceuticals, Inc (ASNS) Delisted Grant (A) — $0 EDGAR
2017-12-01 X4 Pharmaceuticals, Inc (ASNS) Delisted Grant (A) — $0 EDGAR
2017-11-20 X4 Pharmaceuticals, Inc (ASNS) Delisted Mixed +867,639 $3.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.